Vaccine, Johnson & Johnson, Janssen Pharmaceutica, Food and Drug Administration pproves First Long Acting HIV Drug Combo

The treatment was approved by the food and drug administration last week. It involves monthly injections to replace daily pills now used to control hiv. Hiv is a virus that is spread through body fluids. Sexual contact can spread the disease, but so can infected blood and blood products. The two injection combination treatment is called cabineuva. The drug is expected to make it easier for people to receive their hiv medicines and to do so with more privacy. The injections mark a big change from methods used in the past. Those treatments required patients to take multiple pills several times a day carefully. Timed around meals, dr stephen deeks, is an hiv specialist at the university of california san francisco. He told the associated press that the new treatment can make patients lives better because it is only needed once a month. People don’t want those daily reminders that they’re hiv infected deex said cabinet contains realpivorine, which is sold as edurant by jansen a company owned by johnson and johnson. It also contains a new drug called cabategravir. It is made by vive healthcare. The two are sold together and given as separate injections once a month. The drug is also being tested for use every two months, the fda approved cabineuva for use in adults who have had their disease controlled by other hiv medicines and have not shown signs of viral resistance to the two drugs in cabinet. The agency also approved a pill version of kabategravir to be taken with repelvarine for one month to ensure the drugs do not cause bad effects.

Vive said, the injection combination would cost hundred 594 dollars for a higher first dose. The cost would then drop to three thousand nine hundred sixty dollars. Each month the company said this price was similar to what one a day pill combinations cost. Now how much each patient pays depends on their insurance income and other things. Dr judith courier is an hiv specialist at the university of california, los angeles. She said studies on the new treatment found that patients greatly favored the injections. Even people who are taking one pill once a day just reported improvement in their quality of life to switch to an injection. She said courier is an advisor to vive and wrote a commentary about one study on the drug in the new england journal of medicine. Dekes said long acting injections also give hope of reaching groups that have a hard time carrying out daily treatment. He said that includes people with mental illness or substance abuse problems. There’S a great unmet need that the injections may fill he added separately. Vive plans to seek approval for the use of cabategravir to prevent hiv.

What do you think?

Written by freotech


Leave a Reply

Your email address will not be published. Required fields are marked *



Johnson & Johnson, Vaccine, Coronavirus Merck ends Covid vaccine program but continues to work on treatments